Phase II Study of Panitumumab, Nab-paclitaxel, and Carboplatin for Patients With Primary Inflammatory Breast Cancer (IBC) Without HER2 Overexpression

Trial Profile

Phase II Study of Panitumumab, Nab-paclitaxel, and Carboplatin for Patients With Primary Inflammatory Breast Cancer (IBC) Without HER2 Overexpression

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 May 2018

At a glance

  • Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Panitumumab (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil
  • Indications Inflammatory breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Apr 2018 Planned End Date changed from 1 Nov 2018 to 1 Nov 2021.
    • 30 Apr 2018 Planned primary completion date changed from 1 Nov 2018 to 1 Nov 2021.
    • 27 Apr 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top